Why Einstein was right!

29 Januari 2015 Richard van den Broek, Tim Govers

Richard van den Broek

“If you do what you always did, you will get what you always got”

Introduction MedValue

Early HTA: more chances, more value,

and less risks for MedTech companies

Our healthcare needs ways to make medical innovation more affordable, more effective and better voor patients

To find these ways, we need better cooperation between industries, medical doctors/ researchers and patients

Science Meets Business And

Science Needs Business And

Business Needs Science

Science Meets Business And

Science Needs Business And

Business Needs Science What we can add for your business and how we do it

From outside to inside

SLA= Service Level Agreement

Bridge

MedValue BV

Client

Med Tech industry

SLA

SLA

SLA

SLA

TC Radboud 1

(early) HTA incl. Fieldlab

TC Radboud 2

TC Radboud 3

Research

1 Entrance

Implementation = Interactive evaluation / consensus meeting and policy recommendations

Comparative effectiveness studies = In collaboration with other centers

Pilots / Phase II studies = Fieldlab

Why and how: A new approach

Implementation = Interactive evaluation / consensus meeting and

policy recommendations

Comparative effectiveness studies = In collaboration with other centers

Pilots / Phase II studies = Fieldlab

Novel concepts = Dynamic modeling / scenarios / fieldlab

Opportunities = Headroom analyses

Societal needs (patients, clinicians, etc) = Interactive evaluation / scoping

Why and how: A new approach

MedValue

Fieldlabs e.g.

MITeC

The early HTA approach

“How can we convince hospitals and health insurers that our innovation has added value for patients and healthcare?”

“Are there enough oppurtunities to safely invest in the market introduction of our innovation?”

“How can we convince the NZa that our innovation improves health and reduces costs?”

Questions of MedTech companies

“If the innovation could improve diagnosis, what are the potential changes in costs and effects for the healthcare pathway?”

“What is the potential cost-effectiveness of the innovation, which is less invasive than current treatment options?”

Translation into research questions

“What is the maximum price of the innovation for which it is still cost-effective?”

http://www.google.nl/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&docid=XF2m4Gz8kgcFRM&tbnid=x3PcA2LuRRE9jM:&ved=0CAcQjRw&url=http://www.iconarchive.com/show/medical-icons-by-icons-land/People-Patient-Male-icon.html&ei=_iEkVKnAPKXXyQPXkoG4CQ&psig=AFQjCNGjzt9KcrHyVmFjKvgmMZl_8o35cA&ust=1411740266612458

A Current practice

A

X %

1 – x %

A

X %

1 – x %

%

%

%

%

A

B

X %

1 – x %

%

%

%

%

A

B

X %

Y %

1 – Y %

1 – x %

%

%

%

%

A

B

X %

Y %

1 – Y %

1 – x %

%

%

%

%

%

%

%

%

A

B

X %

Y %

1 – Y %

1 – x %

%

%

%

%

%

%

%

%

€

€

€

€

€

€

€

€

A

B

X %

Y %

1 – Y %

1 – x %

%

%

%

%

%

%

%

%

€

€

€

€

€

€

€

€

• “How can we convince decision makers of the added value of PUREtrace?” • “What is the influence of the use of PUREtrace on the

number of unneccessary C-sections?” • “What are the potential cost savings of preventing of C-

sections related to the use of PUREtrace?”

Nemo Healthcare

• Per 1000 deliveries, PUREtrace: • Could prevent 17-76 unnecessary interventions • Could lower direct treatment costs with €5521 – €73086 • May prevent a small number of necessary interventions

(0,13-0,54)

Potential of PUREtrace

What do clients get from MedValue?

• Two-part report based on an independent and evidence based assessment

• Part I: Model structure, evidence and results • Part II: Advice based on results and stakeholder interviews

• Time to deliver: 6 – 8 weeks

Why Einstein was right: what’s new?

• Outside-in approach, 1 gate to knowledge

• Possibility to start much earlier

• Focus on added value for patients and payers

Together we create more value!

Why Einstein was right!

29 Januari 2015 Richard van den Broek, Tim Govers

Richard van den Broek

Sustainability healthcare cost

= New technologies

Only 50% of new treatments better

2030 2010 Year

Push alleen volstaat niet meer

Patients Payers

Med Tech industry

Top referent care teams Reseachers

(technology)Push

- Health gain - Affordable Healthcare

- More profit

-More impact

Creating sustainable Value Always connect the 4 perspectives!

Patients

Med tech industry

Top referent care teams researchers

Payers Health insurance Employers Governments

- Affordable healthcare

- More impact - More profit

- Health gain

MedValue

New drugs vs new intervention focus on safety, not on (cost)effectiveness

Drugs (FDA, EMA)

Phase 1

Phase 2

Phase 3

Phase 4

Devices (…?...)

Not regulated